Celmatix Achieves First Milestone in Women’s Health Drug Discovery Alliance With Evotec

June 3, 2020 12:30 UTC

Evotec licenses novel polycystic ovary syndrome target identified by Celmatix through its Reproductive Atlas™ platform to Bayer

NEW YORK--(BUSINESS WIRE)-- Celmatix Inc., the leading precision health company advancing the field of women’s reproductive medicine, today announced the first milestone has been achieved in its five-year, multi-target alliance with Evotec. This milestone was triggered by Bayer advancing the first drug program centered around a novel Celmatix-identified target from Evotec.

The polycystic ovary syndrome (PCOS) collaboration with Bayer, announced in January, leverages the larger Celmatix-Evotec alliance, a partnership aimed at developing pre-clinical programs for highly prevalent, yet underserved conditions affecting women’s reproductive health including PCOS. Through this partnership, Celmatix, which uses multi-omic data-driven target discovery to focus on women's reproductive health, has elucidated a novel target that will be now be progressed to create new therapies for women with PCOS.

Celmatix founder and CEO, Dr. Piraye Yurttas Beim, explained, "We are thrilled to have achieved this key first milestone so rapidly and feel it is a strong validation of the potential of our Reproductive Atlas platform to help drive transformational change in women’s health therapeutics. For the last decade, Celmatix has made significant investments in this powerful target discovery platform, which consolidates and houses our unique proprietary datasets." She continued, "This not only validates the power of our Reproductive Atlas platform but is also the first vital step in providing a therapeutic solution to the millions of women who suffer from PCOS. We know this is just the beginning of providing much-needed therapeutics for a number of women’s health conditions that have previously been ignored. We're excited to continue to work with leading organizations like Evotec to change the treatment landscape for women."

PCOS is an endocrine disorder that is estimated to impact 10 percent of all women. It is the most frequent cause of female infertility. While the underlying cause of PCOS is largely unknown, genomic studies suggest a strong genetic connection.

"Novel drug targets for the treatment of PCOS are urgently needed. Selecting novel targets with new mechanisms of action on the basis of human patient data is a highly promising approach which should lead to a huge advancement in the field of women's health," stated Dr. Cord Dohrmann, Chief Scientific Officer of Evotec. "Most PCOS patients are managed today with hormonal interventions, such as birth control, that were first introduced more than 50 years ago. We are proud to be working alongside Celmatix and Bayer to address the high unmet need in a critical area of women’s health."

About Celmatix

Celmatix is a data-driven, research-stage precision health company leveraging insights from its proprietary multi-omic discovery platform, Reproductive Atlas, to develop transformational therapeutics in previously underserved areas of women's health. With a lead program in ovarian senescence and additional programs in non-hormonal contraceptives and specialty indications such as endometriosis and polycystic ovary syndrome (PCOS), Celmatix is developing the next generation of interventions in its field and supporting its partners in bringing innovation to a high-value market with large unmet need. For more information visit www.celmatix.com.

About Evotec SE

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005263/en/


Colleen McMillen


Source: Celmatix Inc.

Back to news